^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    EML4-ALK fusion + ALK positive

    i
    Other names: EML4, EMAP Like 4, Restrictedly Overexpressed Proliferation-Associated Protein, Echinoderm Microtubule-Associated Protein-Like 4, Echinoderm Microtubule Associated Protein Like 4, Ropp 120, C2orf2, EMAP-4, EMAPL4, ROPP120, ELP120, NBLST3, CD246, Anaplastic Lymphoma Kinase, Anaplastic Lymphoma Kinase (Ki-1), CD246 Antigen, Mutant Anaplastic Lymphoma Kinase, ALK, ALK Receptor Tyrosine Kinase, Anaplastic Lymphoma Receptor Tyrosine Kinase, ALK Tyrosine Kinase Receptor
    Entrez ID:
    238; 27436
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    3ms
    EML4-ALK gene variants and PD-L1 expression: Their Impact on clinical outcomes in ALK-positive NSCLC (ESMO Asia 2024)
    V3 patients had poor outcomes regardless of PD-L1 status, while V1 patients with PD-L1 negativity had better outcomes. These biomarkers offer key insights into treatment outcomes for ALK-positive patients.
    Clinical • Clinical data • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • EML4 (EMAP Like 4)
    |
    PD-L1 expression • TP53 mutation • ALK positive • PD-L1 negative • EML4-ALK fusion • ALK fusion • ALK mutation • EML4-ALK fusion + ALK positive
    |
    VENTANA PD-L1 (SP263) Assay
    9ms
    HER3 overexpression: a predictive marker for poor prognosis in advanced ALK-positive non-small cell lung cancer treated with ALK inhibitors. (PubMed, Transl Lung Cancer Res)
    Combination treatment with lorlatinib and erlotinib significantly reduced HRG1-induced activation of RTK signaling in ALK-positive NSCLC cells. HER3 overexpression has potential as a prognostic marker in ALK-positive NSCLCs, including ALK-TKI naïve and treated cases, especially those with EML4-ALK V1/V2. Assessing HER3 expression may be crucial for treatment planning and outcome prediction in these patients.
    Journal • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • EML4 (EMAP Like 4) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
    |
    HER-2 expression • ALK positive • EGFR overexpression • MET overexpression • EML4-ALK fusion • ALK fusion • ERBB3 expression • MET expression • ERBB3 overexpression • EML4-ALK fusion + ALK positive • EML4-ALK variant 1
    |
    erlotinib • Lorbrena (lorlatinib)